AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-7. (cancelled)

8. (new) A compound according to formula I:

I



wherein,

X is oxygen, sulphur or a NR^7 group;

R^1 is C_3-C_8 alkyl or C_1-C_8 alkyl substituted by phenoxy or phenyl, both phenoxy or phenyl being optionally substituted by one or more fluoro, chloro, trifluotomethyl, C_1-C_6 alkyl, hydroxyl, or C_1-C_6 alkoxy;

R^2 and R^3 are independently hydrogen, C_1-C_6 alkyl, halogen, trifluoromethyl, hydroxy or C_1-C_6 alkoxy;

R^4 is hydrogen or C_1-C_8 alkyl;

R^5 and R^6 are independently hydrogen or C_1-C_3 alkyl, optionally substituted by hydroxy or phenyl;

R^7 is hydrogen or straight or branched C_1-C_3 alkyl;

Het is a five to seven membered, saturated or unsaturated, heteromonocyclic or an eight to ten membered, saturated or unsaturated, heterobicyclic group, containing one or more heteroatoms chosen independently from nitrogen, oxygen and sulphur, said monocyclic or bicyclic groups being optionally substituted by C_1-C_6 alkyl, halogen, hydroxyl or C_1-C_6 alkoxy; or

the pharmaceutically acceptable salts thereof,

with the proviso that:

Het cannot be indole, benzo[b]furan, benzo[b]thiophen, chroman, when R^5 and R^6 are both hydrogen, or Het cannot be 2-pyridyl;

when R^1 is unsubstituted or substituted benzyl, and R^2 and R^3 are hydrogen, halogen or alkoxy, R^4 is other than hydrogen;

when R^1 is propyl or butyl, R^2, R^3, R^5 and R^6 are hydrogen and R^4 is hydrogen, methyl or ethyl, Het cannot be 1,4-benzodioxan;

when X— R^1 is a para butyloxy group and R^2, R^3, R^4, R^5 and R^6 are hydrogen, Het cannot be 2-thiophenyl, or 4-(2,2'-dimethyl)-pyranyl;

when X— R^1 is an ortho heptyloxy or octyloxy group and R^2, R^3, R^4, R^5 and R^6 are hydrogen, Het cannot be 2-furyl; and

when X– R^1 is an ortho O–$(CH_2)_m$-p-CF_3-phenyl group, where m is an integer from 1 to 3, and R^2, R^3, R^5 and R^6 are hydrogen, Het cannot be pyridyl.

9. (new) A medicament having sodium and/or calcium channel modulating activity and/or selective MAO-B inhibiting activity, said medicament comprising:

a compound according to formula I:

I



wherein,

R^1 is C_3-C_8 alkyl or C_1-C_8 alkyl substituted by phenoxy or phenyl, both phenoxy or phenyl being optionally substituted by one or more fluoro, chloro, trifluotomethyl, C_1-C_6 alkyl, hydroxyl, or C_1-C_6 alkoxy,

R^2 and R^3 are independently hydrogen, C_1-C_6 alkyl, halogen, trifluoromethyl, hydroxy or C_1-C_6 alkoxy,

R^4 is hydrogen or C_1-C_8 alkyl,

R^5 and R^6 are independently hydrogen or C_1-C_3 alkyl, optionally substituted by hydroxy or phenyl,

R^7 is hydrogen or straight or branched C_1-C_3 alkyl,

Het is a five to seven membered, saturated or unsaturated, heteromonocyclic or an eight to ten membered, saturated or unsaturated, heterobicyclic group, containing one or more heteroatoms chosen independently from nitrogen, oxygen and sulphur, said monocyclic or bicyclic groups being optionally substituted by C_1-C_6 alkyl, halogen, hydroxyl or C_1-C_6 alkoxy, or

the pharmaceutically acceptable salts thereof,

with the proviso that:

Het cannot be an indole, chroman when R^5 and R^6 are both hydrogen,

when X– R^1 is an ortho O–$(CH_2)_m$-p-CF_3-phenyl group, where m is an integer from 1 to 3, and R^2, R^3, R^5 and R^6 are hydrogen, Het cannot be pyridyl or the pharmaceutically acceptable salts or prodrug thereof.

10. (new) The medicament according to claim 9, wherein for the compound according to formula I:

R^1 is benzyl or C_5-C_8 alkyl,

R^4, R^5 and R^6 are hydrogen or C_1-C_3 alkyl,

X is oxygen, and

Het is furan, tetrahydrofuran, isoxazol, oxazol, thiophen, pyran, or dioxane, unsubstituted or substituted by C_1-C_3 alkyl.

11. (new) The medicament according to claim 9, wherein the compound according to formula I is selected from the group consisting of:

(4-Pentyloxy-benzyl)-(furan-2-ylmethyl)-amine;

(4-Heptyloxy-benzyl)-(furan-2-ylmethyl)-amine;

(R)(4-Pentyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-amine;

(S) (4-Pentyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-amine;

(R)(4-Heptyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-amine;

(S) (4-Heptyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-amine;

(R)(4-Pentyloxy-benzyl)-(tetrahydro-pyran-2-ylmethyl)-amine;

(S) (4-Pentyloxy-benzyl)-(tetrahydro-pyran-2-ylmethyl)-amine;

(R)(4-Heptyloxy-benzyl)-(tetrahydro-pyran-2-ylmethyl)-amine;

(S) (4-Heptyloxy-benzyl)-(tetrahydro-pyran-2-ylmethyl)-amine;

(4-Benzyloxy-benzyl)-(furan-2-ylmethyl)-amine;

(4-Benzyloxy-benzyl)-(5-methyl-furan-2-ylmethyl)-amine;

[4-(3-Fluoro-benzyloxy)-benzyl]-(furan-2-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(furan-2-ylmethyl)-amine;

[4-(3-Fluoro-benzyloxy)-benzyl]-(5-methyl-furan-2-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(5-methyl-furan-2-ylmethyl)-amine;

(R)(4-Benzyloxy-benzyl)-[1-(furan-2-yl)-1-ethyl]-amine;

(S)(4-Benzyloxy-benzyl)-[1-(furan-2-yl)-1-ethyl]-amine;

[4-(3-Fluoro-benzyloxy)-benzyl]-[1-(furan-2-yl)-1-ethyl]-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-[1-(furan-2-yl)-1-ethyl]-amine;

(R)(4-Benzyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-amine;

(S) (4-Benzyloxy-benzyl)-(tetrahydro-furan-2-ylmethyl)-amine;

(R)[4-(3-Fluoro-benzyloxy)-benzyl]-(tetrahydro-furan-2-ylmethyl)-amine;

(S)[4-(3-Fluoro-benzyloxy)-benzyl]-(tetrahydro-furan-2-ylmethyl)-amine;

(R)[4-(3-Chloro-benzyloxy)-benzyl]-(tetrahydro-furan-2-ylmethyl)-amine;

(S)[4-(3-Chloro-benzyloxy)-benzyl]-(tetrahydro-furan-2-ylmethyl)-amine;

(R)[4-(3-Fluoro-benzyloxy)-benzyl]-(tetrahydro-pyran-2-ylmethyl)-amine;

(S)[4-(3-Fluoro-benzyloxy)-benzyl]-(tetrahydro-pyran-2-ylmethyl)-amine;

(R)[4-(3-Chloro-benzyloxy)-benzyl]-(tetrahydro-pyran-2-ylmethyl)-amine;

(S)[4-(3-Chloro-benzyloxy)-benzyl]-(tetrahydro-pyran-2-ylmethyl)-amine;

(4-Benzyloxy-benzyl)-(1,4-dioxan-2-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(pyrido-2-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(pyrido-3-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(pyrido-4-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(imidazol-2-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(1-methyl-imidazol-2-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(5-methyl-1H-triazol-2-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(4-methyl-thiazol-2-ylmethyl)-amine;

(4-Benzyloxy-benzyl)-(isoxazol-5-ylmethyl)-amine;

[4-(3-Fluoro-benzyloxy)-benzyl]-(isoxazol-5-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(isoxazol-5-ylmethyl)-amine;

(4-Benzyloxy-benzyl)-(3-methyl-isoxazol-5-ylmethyl)-amine;

[4-(3-Fluoro-benzyloxy)-benzyl]-(3-methyl-isoxazol-5-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(3-methyl-isoxazol-5-ylmethyl)-amine;

(4-Benzyloxy-benzyl)-(oxazol-2-ylmethyl)-amine;

[4-(3-Fluoro-benzyloxy)-benzyl]-(oxazol-2-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(oxazol-2-ylmethyl)-amine;

(4-Benzyloxy-benzyl)-(oxazol-5-ylmethyl)-amine;

[4-(3-Fluoro-benzyloxy)-benzyl]-(oxazol-5-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(oxazol-5-ylmethyl)-amine;

(4-Benzyloxy-benzyl)-(thiophen-2-ylmethyl)-amine;

[2-(3-Chloro-benzyloxy)-benzyl]-(thiophen-2-ylmethyl)-amine;

[2-(3-Fluoro-benzyloxy)-benzyl]-(thiophen-2-ylmethyl)-amine;

[3-(3-Chloro-benzyloxy)-benzyl]-(thiophen-2-ylmethyl)-amine;

[3-(3-Fluoro-benzyloxy)-benzyl]-(thiophen-2-ylmethyl)-amine;

[4-(3-Chloro-benzyloxy)-benzyl]-(thiophen-2-ylmethyl)-amine;

[4-(3-Fluoro-benzyloxy)-benzyl]-(thiophen-2-ylmethyl)-amine;

[2-(3-Fluoro-benzyloxy)-benzyl]-(benzo[b]furan-2-ylmethyl)-amine;

[3-(3-Fluoro-benzyloxy)-benzyl]-(benzo[b]furan-2-ylmethyl)-amine;

[4-(3-Fluoro-benzyloxy)-benzyl]-(benzo[b]furan-2-ylmethyl)-amine;

(R)[4-(3-Fluoro-benzyloxy)-benzyl]-(dihydro-benzo[b]furan-2-ylmethyl)-amine;

(S)[4-(3-Fluoro-benzyloxy)-benzyl]-(dihydro-benzo[b]furan-2-ylmethyl)-amine:

[4-(3-Chloro-benzyloxy)-benzyl]-(benzimidazol-2-ylmethyl)-amine;

either as a single isomer or as a mixture of isomers thereof, or the pharmaceutically acceptable salts thereof.

12. (new) A process for the preparation of a compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof, the process comprising:

a) reacting a compound of formula II

II



wherein

X is oxygen, sulphur or a NR^7 group,

R^1 is C_3-C_8 alkyl or C_1-C_8 alkyl substituted by phenoxy or phenyl, both phenoxy or phenyl being optionally substituted by one or more fluoro, chloro, trifluotomethyl, C_1-C_6 alkyl, hydroxyl, or C_1-C_6 alkoxy,

R^2 and R^3 are independently hydrogen, C_1-C_6 alkyl, halogen, trifluoromethyl, hydroxy or C_1-C_6 alkoxy,

with a compound of formula III

III



wherein

R^4 is hydrogen or C_1-C_8 alkyl,

R^5 and R^6 are independently hydrogen or C_1-C_3 alkyl, optionally substituted by hydroxy or phenyl,

R^7 is hydrogen or straight or branched C_1-C_3 alkyl,

Het is a five to seven membered, saturated or unsaturated, heteromonocyclic or an eight to ten membered, saturated or unsaturated, heterobicyclic group, containing one or more heteroatoms chosen independently from nitrogen, oxygen and sulphur, said monocyclic or bicyclic groups being optionally substituted by C_1-C_6 alkyl, halogen, hydroxyl or C_1-C_6 alkoxy,

with the proviso that:

Het cannot be indole, benzo[b]furan, benzo[b]thiophen, chroman, when R^5 and R^6 are both hydrogen, or Het cannot be 2-pyridyl,

when R^1 is unsubstituted or substituted benzyl, and R^2 and R^3 are hydrogen, halogen or alkoxy, R^4 is other than hydrogen,

when R^1 is propyl or butyl, R^2, R^3, R^5 and R^6 are hydrogen and R^4 is hydrogen, methyl or ethyl, Het cannot be 1,4-benzodioxan,

when X– R^1 is a para butyloxy group and R^2, R^3, R^4, R^5 and R^6 are hydrogen, Het cannot be 2-thiophenyl, or 4-(2,2'-dimethyl)-pyranyl,

when X– R^1 is an ortho heptyloxy or octyloxy group and

R^2, R^3, R^4, R^5 and R^6 are hydrogen, Het cannot be 2-furyl, and

when X– R^1 is an ortho O–$(CH_2)_m$-p-CF_3-phenyl group, where m is an integer from 1 to 3, and R^2, R^3, R^5 and R^6 are hydrogen, Het cannot be pyridyl,

in the presence of a reducing agent, or

b) reacting a compound of formula III as defined above with a compound of formula IV,

IV



wherein

X is oxygen, sulphur or a NR^7 group,

R^1 is C_3-C_8 alkyl or C_1-C_8 alkyl substituted by phenoxy or phenyl, both phenoxy or phenyl being optionally substituted by one or more fluoro, chloro, trifluotomethyl, C_1-C_6 alkyl, hydroxyl, or C_1-C_6 alkoxy,

R^2 and R^3 are independently hydrogen, C_1-C_6 alkyl, halogen, trifluoromethyl, hydroxy or C_1-C_6 alkoxy,

Y is a halogen atom or a O-EWG group, where the EWG means an electron withdrawing group, able to transform the oxygen to which the group is linked, into a leaving group and, optionally, converting a compound of the invention into another compound of the invention and/or, optionally, converting the

compound of formula IV into a pharmaceutically acceptable salt and/or, optionally, converting a salt into a free compound.

13. (new) A pharmaceutical composition comprising:

the compound according to claim 8, as an active principle, or a pharmaceutically acceptable salt thereof; and

a suitable carrier and/or diluent and optionally other therapeutic agents.